Management of acute graft-versus-host disease in children

Paul A. Carpenter, Margaret L. MacMillan

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Acute graft-versus-host disease (aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) in children. Although 30% to 50% of children respond to corticosteroids as initial therapy, the optimal initial or second-line therapies have not yet been determined. Newer approaches with combination therapy, novel agents, monoclonal antibodies, and/or cellular therapies show some promise but require prospective well-designed trials that include children to establish their efficacy. This article reviews the clinical presentation, treatment, and practical management guidelines for children with aGVHD.

Original languageEnglish (US)
Pages (from-to)273-295
Number of pages23
JournalPediatric clinics of North America
Issue number1
StatePublished - Feb 2010


  • Acute GVHD
  • Children
  • Graft-versus-host disease
  • Management


Dive into the research topics of 'Management of acute graft-versus-host disease in children'. Together they form a unique fingerprint.

Cite this